The Defense Health Agency awarded The Cleveland Clinic Foundation a $488,198 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to develop and evaluate agents for a poor prognostic vertebrate model for Ewing sarcoma. This 3-year research project, with a performance period from September 1, 2024 to August 31, 2027, will involve the Foundation's senior investigators evaluating new therapeutic agents, including spliceosome inhibitors and compounds identified through zebrafish screening, to advance treatment options for this cancer. As a sub-award under this grant, Case Western Reserve University's Office of Research Administration Division will provide scientific expertise and pathway analysis to support the evaluation of the investigational agents.
Generated 2/25/25, 5:35 AM